Bio-Techne Shareholders Approve Merck Acquisition Amid Ongoing Regulatory Review
Minneapolis-based Bio-Techne has announced that its shareholders have approved the company's proposed acquisition by Merck KGaA, Darmstadt, Germany. The approval marks a significant milestone towards completing the transaction. The companies confirmed that the applicable U.S. antitrust waiting period expired on September 18.
The acquisition remains subject to outstanding regulatory approvals and other customary closing conditions. Completion is expected by late 2026 or early 2027. Bio-Techne shareholders voted to approve the definitive merger agreement under which Merck KGaA proposes to acquire the company.
Kim Kelderman, President and CEO of Bio-Techne, stated, 'We are grateful to our shareholders for their strong support, which marks an important milestone toward completing the transaction.'